Hunan Er Kang Pharmaceutical (300267) - Total Assets
Based on the latest financial reports, Hunan Er Kang Pharmaceutical (300267) holds total assets worth CN¥5.05 Billion CNY (≈ $738.96 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 300267 operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Hunan Er Kang Pharmaceutical - Total Assets Trend (2008–2024)
This chart illustrates how Hunan Er Kang Pharmaceutical's total assets have evolved over time, based on quarterly financial data. See Hunan Er Kang Pharmaceutical book value and equity for net asset value and shareholders' equity analysis.
Hunan Er Kang Pharmaceutical - Asset Composition Analysis
Current Asset Composition (December 2024)
Hunan Er Kang Pharmaceutical's total assets of CN¥5.05 Billion consist of 33.0% current assets and 67.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 13.4% |
| Accounts Receivable | CN¥103.18 Million | 2.0% |
| Inventory | CN¥600.78 Million | 11.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥363.56 Million | 7.0% |
| Goodwill | CN¥2.00 Million | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Hunan Er Kang Pharmaceutical's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Hunan Er Kang Pharmaceutical worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hunan Er Kang Pharmaceutical's current assets represent 33.0% of total assets in 2024, an increase from 0.0% in 2008.
- Cash Position: Cash and equivalents constituted 13.4% of total assets in 2024, up from 12.8% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, a decrease from 8.0% in 2008.
- Asset Diversification: The largest asset category is inventory at 11.6% of total assets.
Hunan Er Kang Pharmaceutical Competitors by Total Assets
Key competitors of Hunan Er Kang Pharmaceutical based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621
|
China | CN¥2.30 Billion |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
|
China | CN¥8.59 Billion |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111
|
China | CN¥925.41 Million |
|
Jw Pharmac
KO:001060
|
Korea | ₩605.27 Billion |
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Samjin Pharm
KO:005500
|
Korea | ₩449.14 Billion |
Hunan Er Kang Pharmaceutical - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.03 | 2.89 | 3.64 |
| Quick Ratio | 1.86 | 1.71 | 2.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.08 Billion | CN¥1.11 Billion | CN¥1.98 Billion |
Hunan Er Kang Pharmaceutical - Advanced Valuation Insights
This section examines the relationship between Hunan Er Kang Pharmaceutical's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.56 |
| Latest Market Cap to Assets Ratio | 0.18 |
| Asset Growth Rate (YoY) | -5.1% |
| Total Assets | CN¥5.20 Billion |
| Market Capitalization | $923.58 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hunan Er Kang Pharmaceutical's assets below their book value (0.18x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Hunan Er Kang Pharmaceutical's assets decreased by 5.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Hunan Er Kang Pharmaceutical (2008–2024)
The table below shows the annual total assets of Hunan Er Kang Pharmaceutical from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.20 Billion ≈ $760.88 Million |
-5.10% |
| 2023-12-31 | CN¥5.48 Billion ≈ $801.76 Million |
-6.43% |
| 2022-12-31 | CN¥5.86 Billion ≈ $856.87 Million |
+7.80% |
| 2021-12-31 | CN¥5.43 Billion ≈ $794.87 Million |
-17.03% |
| 2020-12-31 | CN¥6.55 Billion ≈ $958.00 Million |
+6.56% |
| 2019-12-31 | CN¥6.14 Billion ≈ $899.03 Million |
+1.57% |
| 2018-12-31 | CN¥6.05 Billion ≈ $885.11 Million |
+5.74% |
| 2017-12-31 | CN¥5.72 Billion ≈ $837.03 Million |
+1.18% |
| 2016-12-31 | CN¥5.65 Billion ≈ $827.25 Million |
+17.74% |
| 2015-12-31 | CN¥4.80 Billion ≈ $702.59 Million |
+116.22% |
| 2014-12-31 | CN¥2.22 Billion ≈ $324.94 Million |
+53.46% |
| 2013-12-31 | CN¥1.45 Billion ≈ $211.74 Million |
+16.92% |
| 2012-12-31 | CN¥1.24 Billion ≈ $181.10 Million |
+9.70% |
| 2011-12-31 | CN¥1.13 Billion ≈ $165.09 Million |
+281.43% |
| 2010-12-31 | CN¥295.77 Million ≈ $43.28 Million |
+59.25% |
| 2009-12-31 | CN¥185.73 Million ≈ $27.18 Million |
+51.77% |
| 2008-12-31 | CN¥122.38 Million ≈ $17.91 Million |
-- |
About Hunan Er Kang Pharmaceutical
Hunan Er-Kang Pharmaceutical Co., Ltd manufactures and sells APIs, finished drug products, and pharmaceutical excipients in China and internationally. Its APIs include glycerin, dilute hydrochloric acid, sulbenicillin sodium, dihydroxypropyl theophylline, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. The company's finished drugs primarily comprise sulbenicillin sodium for i… Read more